Methods for increasing levels of interferon activity with an interferon lambda 3 polypeptide

Patent metadata

Field	Value
Publication number	US-10596228-B2
Application number	US-201815869503-A
Country	US
Kind code	B2
Filing date	Jan 12, 2018
Priority date	Feb 8, 2002
Publication date	Mar 24, 2020
Grant date	Mar 24, 2020

Abstract

A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.

First claim

The invention claimed is:

1. A method for upregulating MHC class I antigen expression, said method comprising administering to an individual a composition comprising an effective amount of an interferon lambda 3 (IFN-λ3) polypeptide.

2. The method of claim 1 wherein the IFN-λ3 polypeptide is selected from the group consisting of:
a polypeptide having the complete amino acid sequence of SEQ ID NO: 12; amino acids 2-196 of SEQ ID NO: 12;
amino acids 23-196 of SEQ ID NO: 12;
amino acids 6-196 of SEQ ID NO: 12; amino acids 12-196 of SEQ ID NO: 12;
amino acids 7-196 of SEQ ID NO: 12;
amino acids 13-196 of SEQ ID NO: 12; and
amino acids 31-196 of SEQ ID NO: 12.

3. The method of claim 1 wherein the IFN-λ3 polypeptide is modified by translational or post-translational processing or by a chemical modification technique.

4. The method of claim 3 wherein the IFN-λ3 polypeptide is modified by acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, or transfer-RNA mediated addition of amino acids to proteins.

5. The method of claim 3 wherein the IFN-23 polypeptide is modified by pegylation.

Assignees

• Univ Rutgers

Inventors

• Kotenko Sergei V
• Gallagher Grant F

Classifications

• A61P37/04

  Immunostimulants · CPC title

• C07K14/555 Primary

  Interferons [IFN] · CPC title

• G01N33/6866

  Interferon · CPC title

• C07K14/7156

  for interferons [IFN] · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title